This is a working overview of peptide research, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-02-10 and is reviewed periodically as new material appears.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
A pneumothorax is an abnormal collection of air in the pleural space between the lung and the chest wall. Symptoms typically include sudden onset of sharp, one-sided chest pain and shortness of breath. In a minority of cases, a one-way valve is formed by an area of damaged tissue, and the amount of air in the space between chest wall and lungs increases; this is called a tension pneumothorax. This can cause a steadily worsening oxygen shortage and low blood pressure. This leads to a type of shock called obstructive shock, which can be fatal unless reversed. Very rarely, both lungs may be affected by a pneumothorax. It is often called a "collapsed lung", although that term may also refer to atelectasis. Divers who breathe from an underwater apparatus are supplied with breathing gas at ambient pressure, which results in their lungs containing gas at higher than atmospheric pressure. Divers breathing compressed air (such as when scuba diving) may develop a pneumothorax as a result of barotrauma from ascending just 1 metre (3 ft) while breath-holding with their lungs fully inflated. An additional problem in these cases is that those with other features of decompression sickness are typically treated in a diving chamber with hyperbaric therapy; this can lead to a small pneumothorax rapidly enlarging and causing features of tension. Diagnosis of a pneumothorax by physical examination alone can be difficult (particularly in smaller pneumothoraces). A chest X-ray, computed tomography (CT) scan, or ultrasound is usually used to confirm its presence.
=== Injury and workload === Fractures to bones during or after excavation appear relatively fresh, with broken surfaces appearing white and unweathered. Distinguishing between fractures around the time of death and post-depositional fractures in bone is difficult, as both types of fractures show signs of weathering. Unless evidence of bone healing or other factors are present, researchers may choose to regard all weathered fractures as post-depositional. Evidence of perimortal fractures (or fractures inflicted on a fresh corpse) can be distinguished in unhealed metal blade injuries to the bones. Living or freshly dead bones are somewhat resilient, so metal blade injuries to bone generate a linear cut with relatively clean edges rather than irregular shattering. Archaeologists have attempted to use the microscopic parallel scratch marks on cut bones in order to estimate the trajectory of the blade that caused the injury.
== Metabolism == Metabolism of this compound has been assessed, revealing diclazepam has an approximate elimination half-life of 42 hours and undergoes N-demethylation to delorazepam, which can be detected in urine for 6 days following administration of the parent compound. Other metabolites detected were lorazepam and lormetazepam which were detectable in urine for 19 and 11 days, respectively, indicating hydroxylation by cytochrome P450 enzymes occurring concurrently with N-demethylation.
It is usually well tolerated, though overdose toxicity is possible. Occasionally side effects include headache, numbness, and sleepiness. Pyridoxine overdose can cause a peripheral sensory neuropathy characterized by poor coordination, numbness, and decreased sensation to touch, temperature, and vibration. Healthy human blood levels of pyridoxine are 2.1–21.7 ng/mL. Normal doses are safe during pregnancy and breastfeeding.
=== Anticarcinogenic activity === The anticancer activity of bovine lactoferrin (bLF) has been demonstrated in experimental lung, bladder, tongue, colon, and liver carcinogeneses on rats, possibly by suppression of phase I enzymes, such as cytochrome P450 1A2 (CYP1A2). Also, in another experiment done on hamsters, bovine lactoferrin decreased the incidence of oral cancer by 50%. Currently, bLF is used as an ingredient in yogurt, chewing gums, infant formulas, and cosmetics.
Sources: en.wikipedia.org
== Further reading == Wolfram-Schauerte, Maik; Pozhydaieva, Nadiia; Grawenhoff, Julia; Welp, Luisa M.; Silbern, Ivan; Wulf, Alexander; Billau, Franziska A.; Glatter, Timo; Urlaub, Henning; Jäschke, Andres; Höfer, Katharina (August 16, 2023). "A viral ADP-ribosyltransferase attaches RNA chains to host proteins". Nature. 620 (7976): 1054–1062. Bibcode:2023Natur.620.1054W. doi:10.1038/s41586-023-06429-2. PMC 10468400. PMID 37587340.
=== 2014 === On January 22, 2014, European Southern Observatory became the first scientific organization to deliver Ultra HD footage at regular intervals. On May 6, 2014, France announced DVB-T2 tests in Paris for Ultra HD HEVC broadcast with objectives to replace by 2020 the current DVB-T MPEG4 HD national broadcast. On May 26, 2014, satellite operator Eutelsat announced the launch of Europe's first Ultra HD demo channel in HEVC, broadcasting at 50 fps. The channel is available on the Hot Bird satellites and can be watched by viewers with 4K TVs equipped with DVB-S2 demodulators and HEVC decoders. In June 2014, the FIFA World Cup of that year (held in Brazil) became the first shot entirely in 4K Ultra HD, by Sony. The European Broadcasting Union (EBU) broadcast matches of the FIFA World Cup to audiences in North America, Latin America, Europe and Asia in Ultra HD via SES' NSS-7 and SES-6 satellites. Indian satellite TV provider unveils its plan to launch 4K UHD service early in 2015 and showcased live FIFA World Cup quarter final match in 4K UHD through Sony Entertainment Television Sony SIX. On June 24, 2014, the CEA updated the guidelines for Ultra High-Definition and released guidelines for Connected Ultra High-Definition, adding support for internet video delivered with HEVC. The CEA is developing a UHD logo for voluntary use by companies that make products that meet CEA guidelines. The CEA also clarified that "Ultra High-Definition", "Ultra HD", or "UHD" can be used with other modifiers and gave an example with "Ultra High-Definition TV 4K".
== Structure == Properdin is a gamma globulin protein composed of multiple identical protein subunits with a separate ligand-binding site. Native properdin occurs in head-to-tail dimers, trimers and tetramers in the fixed ratio 22:52:28. Under physiological conditions, properdin forms P2, P3, and P4 in a 26:54:20 ratio by a head-to-tail formation of monomers. The structure is a single-chain molecule made of 469 amino acids, with the leader sequence consisting of 27-amino acids. Every properdin monomer is made of six thrombospondin type 1 repeat (TSR) domains labeled TSR1-6, each including a core of three antiparallel strands with three disulfides, totaling 60 amino acids. Properdin undergoes post-translation through C-mannosylation, O-fucosylation, N-glycosylation, and C-glycosylation.
=== Two-stroke engines === A rotary valve in the form of a flat disc, also known as a disc valve, is used in two-stroke motorcycle engines, where the arrangement helps to prevent reverse flow back into the intake port during the compression stroke. Austrian engine manufacturer Rotax used rotary intake valves in their now out-of-production 64 hp (48 kW) Rotax 532 two-stroke engine design and continues to use rotary intake valves in the 532's successor, the current-production 64 hp (48 kW) Rotax 582. Wifredo Ricart, a Spanish engineer who worked at Alfa Romeo and then in Pegaso, who had applied for the 'Desmodromic' valve drive system in 1924, patent FR590149; patented, ES166367, 1944, a Rotary Valve for 2-Strokes; also an Itala type of Valve, patent ES0117737. Lotus tried something similar, SAE technical paper 920779.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.